{"product_id":"nrc-vrio-analysis","title":"National Research Corporation (NRC): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to National Research Corporation (NRC)'s enduring success! This VRIO Analysis cuts straight to the core, revealing precisely how the firm's Value, Rarity, Inimitability, and Organization translate into sustainable competitive advantage, summarized by the key findings in \u0026amp;O4\u0026amp;. Dive in now to discover the tangible resources driving their market position and what it means for their future performance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNational Research Corporation (NRC) - VRIO Analysis: 1. Subscription Business Model\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at National Research Corporation (NRC) and seeing the undeniable strength of its recurring revenue engine, which is the key to its valuation, even with some near-term margin noise. The direct takeaway is that the subscription model is the durable competitive advantage, evidenced by the $\\text{Q3 2025}$ figures.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the $\\text{Q3 2025}$ scorecard that underpins this model:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMetric\u003c\/td\u003e\n    \u003ctd\u003eValue (Q3 2025)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTotal Recurring Contract Value (TRCV)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$141.7 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTRCV Year-over-Year Growth\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e8%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTotal Revenue\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$34.6 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e31%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash Flow from Operations\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e\\$13.8 million\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Predictable Financial Backbone\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe subscription model provides highly predictable, recurring revenue, which is the backbone of financial stability. This is clearly evidenced by the \u003cstrong\u003e\\$141.7 million\u003c\/strong\u003e Total Recurring Contract Value (TRCV) as of $\\text{Q3 2025}$. This forward-looking metric shows clients are committed to multi-year data services, which is exactly what you want to see in a service provider.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderately Rare in Healthcare Analytics\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis structure is moderately rare; many competitors in the healthcare intelligence space still rely on project-based work or lower-retention software contracts. NRC Health’s deep embedding within a hospital system’s annual measurement and improvement cycles makes its recurring revenue base less common than transactional competitors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult Due to High Switching Costs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt’s difficult for a competitor to copy this moat quickly. Switching costs for healthcare systems already embedded in NRC Health’s annual measurement cycles are high, especially when the CEO, Trent Green, noted a meaningful improvement in customer retention and the best quarterly customer expansion activity in six years. If onboarding takes 14+ days, churn risk rises, but here, the stickiness is structural.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Strong Alignment with Model Growth\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization is clearly driving sequential TRCV growth for four straight quarters. Furthermore, management signaled confidence by increasing the quarterly cash dividend by \u003cstrong\u003e33%\u003c\/strong\u003e to \u003cstrong\u003e\\$0.16\u003c\/strong\u003e per share, which is a strong organizational commitment to shareholder returns based on the recurring cash flow.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eOpportunity: Strong $\\text{TRCV}$ growth suggests future revenue acceleration.\u003c\/li\u003e\n  \u003cli\u003eRisk: Certain marketing expenses may return in $\\text{Q4 2025}$, pressuring near-term margins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe recurring nature of the revenue, combined with high switching costs in the critical patient experience measurement space, creates a durable moat against transactional competitors. This is a sustained competitive advantage, provided they keep innovating their AI-enabled solutions.\u003c\/p\u003e\n\u003cp\u003eFinance: draft $\\text{13}$-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNational Research Corporation (NRC) - VRIO Analysis: 2. Proprietary Human Understanding® Methodology\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe unique, empathic framework differentiates insights, helping clients build trust, which is the core mandate for healthcare leaders. NRC Health received the esteemed \u003cstrong\u003e2025 Best in KLAS Award for Healthcare Experience Management\u003c\/strong\u003e for the second time in three years.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eRare; a deeply ingrained, trademarked approach built over \u003cstrong\u003e40+ years\u003c\/strong\u003e of industry leadership.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eVery difficult; requires institutional knowledge and cultural adoption, not just purchasing a dataset. The methodology is based on rigorous scientific development involving \u003cstrong\u003e5\u003c\/strong\u003e focus groups and analysis of \u003cstrong\u003e115\u003c\/strong\u003e existing questions across over \u003cstrong\u003e900\u003c\/strong\u003e surveys.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eExcellent; central to brand and product narrative, validated by the \u003cstrong\u003e2025 Best in KLAS Award\u003c\/strong\u003e. The methodology is supported by the Market Insights study measuring over \u003cstrong\u003e300,000\u003c\/strong\u003e people annually and Experience Touchpoints registering over \u003cstrong\u003e25 million\u003c\/strong\u003e responses in the past year (as of 2023 data).\u003c\/p\u003e\n\u003cp\u003eBehavioral signs of Human Understanding boil down to three themes:\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eConnect with me\u003c\/li\u003e\n\u003cli\u003eListen to me\u003c\/li\u003e\n\u003cli\u003ePartner with me\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eSustained; this intellectual property is a core differentiator in experience management, evidenced by the following quantifiable impacts:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\/Finding\u003c\/td\u003e\n\u003ctd\u003eQuantification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHUme as NPS Driver\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e#1\u003c\/strong\u003e driver of Net Promoter Score (NPS)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePromoter Odds Increase (with HUme)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e12 times higher\u003c\/strong\u003e odds of being a Promoter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e'Excellent' Rating Likelihood Increase\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e295%\u003c\/strong\u003e more likely to rate overall image\/reputation as “excellent”\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLoyalty Rate (with HUme)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e86%\u003c\/strong\u003e profess loyalty to the organization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGundersen Health System NPS Gain\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3 points\u003c\/strong\u003e growth post-implementation (Jan 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eM Health Fairview NPS Gain\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4 points\u003c\/strong\u003e increase post-implementation (Dec 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdoption Rate\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e80\u003c\/strong\u003e health organizations implemented the HUme\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$34.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Total Recurring Contract Value (TRCV)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$141.7 million\u003c\/strong\u003e (\u003cstrong\u003e8%\u003c\/strong\u003e YoY increase)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTRCV Loss Reduction\u003c\/td\u003e\n\u003ctd\u003eNearly \u003cstrong\u003e50%\u003c\/strong\u003e reduction in TRCV losses\/down sells due to improved retention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eNational Research Corporation (NRC) - VRIO Analysis: 3. Healthcare Experience Data Assets\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eMassive, longitudinal datasets on patient, employee, and consumer experience across thousands of organizations fuel their analytics and AI capabilities.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eRare; the sheer volume and depth of historical, proprietary healthcare experience data are unmatched by newer entrants.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eVery difficult; competitors would need decades of consistent data collection to match this scale.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eWell-organized; the platform integrates this data to deliver actionable insights, leading to a strong \u003cstrong\u003e31%\u003c\/strong\u003e Adjusted EBITDA margin in Q3 2025.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eSustained; data scale creates a network effect for better predictive models.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric Category\u003c\/td\u003e\n\u003ctd\u003eSpecific Metric\u003c\/td\u003e\n\u003ctd\u003eReal-Life Number\/Amount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eData Volume\/Scope\u003c\/td\u003e\n\u003ctd\u003eAnnual Participants in Largest Consumer Perception Study\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e300,000\u003c\/strong\u003e people annually\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData Volume\/Scope\u003c\/td\u003e\n\u003ctd\u003ePatient Responses Collected via Short-Form Tools (Past Year)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e25 million\u003c\/strong\u003e responses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$34.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e31.4%\u003c\/strong\u003e or \u003cstrong\u003e31%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eTotal Recurring Contract Value (TRCV)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$141.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eCash Flow from Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe scale of data collection supports the VRIO framework elements:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eData Scope: Largest online healthcare-consumer perception study in the U.S.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eData Depth: Experience surveys gathered most data within 48 hours of a clinical encounter.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFinancial Output: TRCV grew \u003cstrong\u003e8%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e$141.7 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNational Research Corporation (NRC) - VRIO Analysis: 4. Industry Recognition and Brand Trust\n\u003c\/h2\u003e\n\n\u003cp\u003e\nThe industry recognition component of NRC's intangible assets is assessed based on its consistent performance validated by third-party industry benchmarks.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eVRIO Assessment Components:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment Detail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eThe \u003cstrong\u003e2025 Best in KLAS Award\u003c\/strong\u003e for Healthcare Experience Management acts as a powerful, third-party validation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eRare; winning a top industry award like Best in KLAS is an annual achievement that few competitors secure, evidenced by winning the award for the \u003cstrong\u003esecond time in three years\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult; reputation and trust must be earned over many years of consistent performance and client success, supported by \u003cstrong\u003emore than 40 years\u003c\/strong\u003e in operation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eEffective; management clearly leverages this recognition in marketing and sales pitches, with formal recognition scheduled for \u003cstrong\u003eMarch 3, 2025\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary; while strong, awards can be won by others next year, though the underlying trust is more durable, operating within a company with a \u003cstrong\u003eMarket Cap of $359.57M\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eSupporting Statistical and Financial Data:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNRC Health received the \u003cstrong\u003e2025 Best in KLAS Award\u003c\/strong\u003e for Healthcare Experience Management.\u003c\/li\u003e\n\u003cli\u003eThe company has been in operation for \u003cstrong\u003emore than 40 years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe 2025 award marks the \u003cstrong\u003esecond time in three years\u003c\/strong\u003e NRC Health has received this specific recognition.\u003c\/li\u003e\n\u003cli\u003eNRC Health’s Market Insights study measures insights from \u003cstrong\u003emore than 310,000 individuals annually\u003c\/strong\u003e for its Consumer Loyalty Awards.\u003c\/li\u003e\n\u003cli\u003eThe 2025 Consumer Loyalty Awards selection is based on Net Promoter Scores (NPS) from \u003cstrong\u003eApril 1, 2024, through March 31, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNational Research Corporation (NRC) had \u003cstrong\u003eannual revenue of $143.06M\u003c\/strong\u003e in the year 2024.\u003c\/li\u003e\n\u003cli\u003eThe trailing twelve months (TTM) revenue as of the quarter ending September 30, 2025, was \u003cstrong\u003e$139.10M\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's Market Cap was reported at \u003cstrong\u003e$359.57M\u003c\/strong\u003e, with \u003cstrong\u003e368 employees\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNational Research Corporation (NRC) - VRIO Analysis: 5. Extensive Client Footprint and Market Reach\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Serving a significant base of healthcare organizations across the US and Canada provides a massive base for cross-selling and market intelligence gathering. The Market Insights database gathers data from more than \u003cstrong\u003e310,000 respondents\u003c\/strong\u003e reporting from \u003cstrong\u003e300 different markets\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately rare; penetration across acute and long-term care sectors is significant, evidenced by the recurring contract value metrics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Costly and time-consuming; establishing relationships with a large number of health systems requires substantial time investment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Organized; evidenced by strong forward-looking sales momentum and recent financial performance metrics.\u003c\/p\u003e\n\u003cp\u003eThe organization's subscription core shows resilience, as reflected in the Total Recurring Contract Value (TRCV) growth:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTRCV as of Q3 2025 reached \u003cstrong\u003e$141.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTRCV represented an \u003cstrong\u003e8%\u003c\/strong\u003e year-over-year increase as of Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003e8%\u003c\/strong\u003e TRCV growth in Q3 2025 was the strongest since 2020.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe following table details key financial figures for the quarter ending September 30, 2025 (Q3 2025):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eChange\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$34.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eA \u003cstrong\u003e2%\u003c\/strong\u003e increase sequentially from the previous quarter.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing Twelve Months (TTM) Revenue (as of Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$139.10 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eA year-over-year decline of \u003cstrong\u003e-3.51%\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Recurring Contract Value (TRCV) (as of Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$141.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAn \u003cstrong\u003e8%\u003c\/strong\u003e year-over-year increase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Net Income (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eA \u003cstrong\u003e27.5%\u003c\/strong\u003e decrease from the prior year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow from Operations (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eA jump of \u003cstrong\u003e46%\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio (MRQ 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.53\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates a tight liquidity position on paper.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company has also signaled confidence through capital allocation decisions:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe dividend was increased by \u003cstrong\u003e33%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the established installed base and recurring revenue base act as a barrier to entry for new competitors, supported by the \u003cstrong\u003e$141.7 million\u003c\/strong\u003e TRCV.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNational Research Corporation (NRC) - VRIO Analysis: 6. Total Recurring Contract Value (TRCV) Momentum\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Total Recurring Contract Value (TRCV) was $141.7 million as of Q3 2025, representing a 40% sequential growth in cash flow from operations to $13.8 million for the quarter.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Q3 2025 TRCV increased 8% year-over-year to $141.7 million, marking the strongest growth since 2020.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e TRCV losses and down sells were reduced by nearly 50%. The net retention rate achieved its highest level since 2020. Customer expansion activity was reported as the best in six years.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Management specifically highlighted drivers for TRCV momentum:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eReduced TRCV losses and downsells by nearly 50%.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eAchieved the highest net retention rate since 2020.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eReported the best quarterly customer expansion activity in six years.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eAnnounced a 33% increase in the quarterly cash dividend to $0.16 per share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e The current momentum is evidenced by four consecutive quarters of sequential TRCV growth.\u003c\/p\u003e\n\n\u003cp\u003eKey Financial Metrics for Context (Q3 2025):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eContext\/Comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Recurring Contract Value (TRCV)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$141.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e8%\u003c\/strong\u003e year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$34.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e2%\u003c\/strong\u003e quarter-over-quarter\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e11%\u003c\/strong\u003e year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpanded over \u003cstrong\u003e4\u003c\/strong\u003e percentage points from Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow from Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e46%\u003c\/strong\u003e year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eNational Research Corporation (NRC) - VRIO Analysis: 7. Integrated Solutions Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to sell across Patient, Employee, and Market Experience allows for larger contract sizes and deeper integration into client operations.\u003c\/p\u003e\n\u003cp\u003eThe integrated portfolio drives significant forward-looking revenue, evidenced by the Total Recurring Contract Value (TRCV) reaching \u003cstrong\u003e$141.7 million\u003c\/strong\u003e as of Q3 2025, representing an \u003cstrong\u003e8%\u003c\/strong\u003e year-over-year increase. This metric reflects the stickiness and increased scope of bundled contracts. The value proposition is underscored by the estimated lifetime value of each customer\/patient being \u003cstrong\u003e$1.2 million\u003c\/strong\u003e for health systems.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Recurring Contract Value (TRCV)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$141.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTRCV Year-over-Year Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClient Base Penetration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOver 260\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTop 400 healthcare systems (as of 12\/31\/2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePromoter NPS (Human-Centered Care)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e81\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompared to non-promoters NPS of \u003cstrong\u003e5\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately rare; many competitors focus on only one or two experience dimensions.\u003c\/p\u003e\n\u003cp\u003eNRC Health's comprehensive platform covering multiple experience dimensions is recognized by industry benchmarks:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReceived the \u003cstrong\u003e2025 Best in KLAS Award\u003c\/strong\u003e for Healthcare Experience Management.\u003c\/li\u003e\n\u003cli\u003eReceived the \u003cstrong\u003e2023 Best in KLAS Award\u003c\/strong\u003e for Patient Experience Improvement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderately difficult; requires successful past acquisitions or significant internal R\u0026amp;D investment to bundle effectively.\u003c\/p\u003e\n\u003cp\u003eThe bundling capability is supported by strategic investments, such as the acquisition of Patient Wisdom in 2021, which enhanced the MyStory solution for capturing patient-generated contextual data integrated into the EHR. Furthermore, the company has integrated solutions like Nobl's rounding capabilities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Developing; the focus on modernizing the technology platform suggests ongoing efforts to better integrate these modules.\u003c\/p\u003e\n\u003cp\u003eOrganizational structure has been recently adapted to capitalize on growth runways:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIn January 2024, new leadership roles were added, including Chief Revenue Officer, Chief Customer Officer, Chief Product Technology Officer, and Chief Corporate Development Officer.\u003c\/li\u003e\n\u003cli\u003eThe platform is being modernized with an AI-enabled product suite, including the Huey™ AI engine.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; integration creates stickiness and makes the total solution more valuable than component parts.\u003c\/p\u003e\n\u003cp\u003eThe integrated approach yields measurable superior outcomes, creating a high barrier to substitution. Patients experiencing human-centered care are \u003cstrong\u003e12x\u003c\/strong\u003e more likely to be promoters, resulting in a collective Net Promoter Score (NPS) of \u003cstrong\u003e81\u003c\/strong\u003e, significantly higher than the \u003cstrong\u003e5\u003c\/strong\u003e NPS delivered by those not experiencing that level of care.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNational Research Corporation (NRC) - VRIO Analysis: 8. Strong Cash Flow Generation\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to convert revenue to cash funds strategic flexibility, investment in R\u0026amp;D (like AI initiatives), and shareholder returns. Q3 2025 Cash Flow from Operations was \u003cstrong\u003e\\$13.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately rare; Q2 2025 showed margin compression, but Q3 2025 cash flow surged \u003cstrong\u003e46%\u003c\/strong\u003e year-over-year, indicating strong working capital management.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; it relies on profitability and efficient collections, which are hard to force quickly.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Improving; the significant cash flow jump suggests the new leadership is focusing on operational discipline.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; cash flow can be volatile, but the recent surge shows strong organizational focus.\u003c\/p\u003e\n\n\u003cp\u003eThe operational efficiency driving cash flow generation is evidenced by key financial metrics across recent quarters:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Actual\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Actual\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$34,038,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$34.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow from Operations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$5.507 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$13.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow from Operations as % of Revenue\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated as 40%\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Margin \/ Adjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5%\u003c\/strong\u003e Operating Margin\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e31%\u003c\/strong\u003e Adjusted EBITDA Margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe organizational focus on operational discipline and capital allocation is further supported by specific Q3 2025 achievements:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Recurring Contract Value (TRCV) increased \u003cstrong\u003e8%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e\\$141.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTRCV losses\/downsells were reduced nearly \u003cstrong\u003e50%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe quarterly dividend was increased \u003cstrong\u003e33%\u003c\/strong\u003e to \u003cstrong\u003e\\$0.16\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eThe company repurchased \u003cstrong\u003e618,264 shares\u003c\/strong\u003e at an average price of \u003cstrong\u003e\\$14.99\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA was \u003cstrong\u003e\\$10.9 million\u003c\/strong\u003e, an \u003cstrong\u003e11%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNational Research Corporation (NRC) - VRIO Analysis: 9. Commitment to Shareholder Returns\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e An aggressive capital return program, including a 33% dividend increase to \\$0.16 per share declared in October 2025, signals management confidence in future earnings. The company returned a total of \\$28.1 million to shareholders through dividends and stock repurchases during 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately rare; funding capital returns via share repurchases and dividend increases while maintaining modest leverage and positive cash flow generation is a bold, though risky, move.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires board approval and the financial capacity to execute the buybacks and dividends, supported by Q3 2025 Adjusted EBITDA of \\$10.9 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Clear; the company has a defined policy for returning value, which attracts a certain class of investor, as evidenced by the forward annual dividend of \\$0.64 per share and a forward payout ratio of 73.24%.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this is a financial policy choice, not an operational advantage, and can be reversed if performance falters, as seen by the 0 successive years of dividend increases as of March 2025.\u003c\/p\u003e\n\u003cp\u003eFinance: Draft 13-week cash view by Friday.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Capital Allocation Metrics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Quarterly Cash Dividend Declared: \\$0.16 per share.\u003c\/li\u003e\n\u003cli\u003ePrevious Quarterly Dividend: \\$0.12 per share.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Share Repurchase Volume: 618,264 shares.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Share Repurchase Value: \\$9.3 million.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 Share Repurchase Volume: 382,000 shares.\u003c\/li\u003e\n\u003cli\u003eApril 2025 Closed Buyback Volume: 1,000,000 shares.\u003c\/li\u003e\n\u003cli\u003eApril 2025 Closed Buyback Value: \\$14.98 million.\u003c\/li\u003e\n\u003cli\u003eQ4 2024 Dividend Payment: Approximately \\$2.8 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eSelected Financial Data Supporting Capital Returns:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Return to Shareholders\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$28.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDuring 2025 (YTD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Recurring Contract Value (TRCV)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$141.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 End\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$34.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP Net Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$4.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$10.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Indebtedness (Total Borrowing minus Cash)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e\\$58.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516218204309,"sku":"nrc-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/nrc-vrio-analysis.png?v=1740197740","url":"https:\/\/dcf-model.com\/fr\/products\/nrc-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}